Two-Drug combo targets tough lung cancers in early trial
NCT ID NCT05704634
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 24 times
Summary
This early-phase study tests whether combining two drugs—sarilumab (Kevzara) and cemiplimab—can help control certain types of advanced non-small cell lung cancer. About 56 adults with EGFR or LKB1/STK11 gene mutations will receive the combination. The main goal is to check safety and side effects, while also looking for signs that the treatment shrinks or slows tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.